Abstract
Regional Metastatic Melanoma has a relatively high mortality rate. Adjuvant interferon-alpha (IFN-α) has been shown to improve disease-free survival, post-resection. Cardiotoxicity associated with IFN-α use has been described previously in the literature, but here we describe the first case of pericardial effusion with cardiac tamponade secondary to IFN-α 2b treatment of melanoma. Clinicians should be aware of this potentially lethal complication and the possible acuity of its onset.
This is a preview of subscription content, log in via an institution to check access.
References
Charles MB, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.
Slijfer S, et al. Side effects of interferon-a treatment. Pharm World Sci. 2005;27(6):423–31.
Sonnenblick M, Rosin A. Cardiotoxicity of interferon A review of 44 cases. Chest. 1991;99(3):557–61.
Cohen M, Huberman M, Nesto R. Recombinant alpha 2 interferon- related cardiomyopathy. Am J Med. 1988;85:549–51.
Zimmerman S, et al. Irreversible, severe congestive cardiomyopathy occurring in association with interferon alpha therapy. Cancer Biother. 1994;9(4):291–9.
Kruit WH, et al. Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpected frequent complication. Cancer. 1994;74(10):2850–6.
Teragawa H, et al. Cardiogenic shock following recombinant alpha-2b interferon therapy for chronic hepatitis C. A case report. Jpn Heart J. 1996;31(1):137–42.
Sikole A, et al. Treatment of hepatitis C in hemodialysis patients with pegulated interferon alpha-2a as monotherapy. Ren Fail. 2007;29:961–1099.
Boonen A, Stockbrugger RW, van der Linden S. Pericarditis after therapy with interferon-alpha for chronic hepatitis C. Clin Rheumatol. 1999;18:177–9.
Nikolaidis LA, et al. Hepatitis C virus-associated pericardial effusion and tamponade in liver transplant recipient. Can J Cardiol. 2004;20(7):719–21.
Vacher-Coponat H, et al. Thrombotic microangiopathy in a patient with chronic myelocytic leukaemia treated with alpha interferon. Nephrol Dial Transplant. 1994;14:2469–71.
Khakoo AY, Halushka MK, Rame JE. Reversible cardiomyopathy caused by administration of interferon α. Nat Clin Prac Cardiovascular Med. 2005;2(1):53–7.
Benjamini O, Kimhi O, Lishner M. Severe pleuropericarditis and cardiomyopathy induced by high dose interferon alpha-2b. IMAJ. 2007;9:486–7.
Hauschild A, et al. Practical guidelines for the management of interferon-a-2b Side effects in patients receiving adjuvant treatment for melanoma. Cancer. 2008;112(5):982–94.
Lin CT, et al. Myxedema associated with cardiac tamponade. Jpn Heart J. 2003;44(3):447–50.
Gogas H, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709–18.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rauw, J., Ahmed, S. & Petrella, T. Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma. Med Oncol 29, 1304–1307 (2012). https://doi.org/10.1007/s12032-011-9935-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-011-9935-7